Want to stay updated on the latest news?
Create a Reader Account today to follow the industries and companies that interest you, and customize your news dashboard. SIGN INTO READER ACCOUNT CREATE READER ACCOUNT
Adverum Biotechnologies Appoints Star Seyedkazemi, Pharm.D. as Chief Development Officer
January 06, 2022 16:05 ET
|
Adverum Biotechnologies, Inc.
REDWOOD CITY, Calif., Jan. 06, 2022 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage gene therapy company targeting unmet medical needs in ocular and rare diseases,...
Adverum Biotechnologies Provides ADVM-022 Development Update and Anticipated Corporate Milestones for 2022
December 21, 2021 08:00 ET
|
Adverum Biotechnologies, Inc.
- Finalizing Two-Dose Study Design for Phase 2 Trial of ADVM-022 in Wet AMDwith Intention to Dose First Patient in Q32022 - - Anticipates Near-term Hires to Further Strengthen Executive Team - -...
Adverum Biotechnologies Appoints Rupert D’Souza, Ph.D., M.B.A. as Chief Financial Officer
December 06, 2021 09:00 ET
|
Adverum Biotechnologies, Inc.
REDWOOD CITY, Calif., Dec. 06, 2021 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage gene therapy company targeting unmet medical needs in ocular and rare diseases,...
Adverum Reports Third Quarter 2021 Results
November 04, 2021 16:05 ET
|
Adverum Biotechnologies, Inc.
REDWOOD CITY, Calif., Nov. 04, 2021 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage gene therapy company targeting unmet medical needs in ocular and rare diseases,...
Adverum Presents Clinical Data on ADVM-022 at the American Society of Retina Specialists 39th Annual Scientific Meeting
October 09, 2021 11:17 ET
|
Adverum Biotechnologies, Inc.
REDWOOD CITY, Calif., Oct. 09, 2021 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage gene therapy company targeting unmet medical needs in ocular and rare diseases,...
Adverum Presents 2-Year OPTIC Data Demonstrating Sustained Durability and Promising Safety Profile from Single Intravitreal Injection of ADVM-022 in Wet AMD Patients Who Previously Required Frequent Anti-VEGF Injections
October 01, 2021 16:00 ET
|
Adverum Biotechnologies, Inc.
-- Results featured in a presentation today at the Retina Society’s 54th Annual Scientific Meeting -- -- Robust aflibercept protein expression sustained through 2 years -- -- Over 80% reduction...
Adverum Appoints Global Regulatory Leader Jim Wang, Ph.D., as Senior Vice President, Head of Regulatory Affairs
August 23, 2021 09:00 ET
|
Adverum Biotechnologies, Inc.
REDWOOD CITY, Calif., Aug. 23, 2021 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage gene therapy company targeting unmet medical needs in ocular and rare diseases,...
Adverum Reports Second Quarter 2021 Results
August 05, 2021 16:05 ET
|
Adverum Biotechnologies, Inc.
REDWOOD CITY, Calif., Aug. 05, 2021 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage gene therapy company targeting unmet medical needs in ocular and rare diseases,...
Adverum Stockholders Re-Elect All Adverum Director Nominees at 2021 Annual Meeting
May 12, 2021 13:05 ET
|
Adverum Biotechnologies, Inc.
REDWOOD CITY, Calif., May 12, 2021 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage gene therapy company targeting unmet medical needs in ocular and rare diseases,...
Adverum Reports First Quarter 2021 Results
May 06, 2021 16:00 ET
|
Adverum Biotechnologies, Inc.
REDWOOD CITY, Calif., May 06, 2021 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage gene therapy company targeting unmet medical needs in ocular and rare diseases,...